A phase 3 pivotal study of bimatoprost
Latest Information Update: 22 Nov 2024
Price :
$35 *
At a glance
- Drugs Bimatoprost (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Registrational; Therapeutic Use
- 22 Nov 2024 New trial record
- 19 Nov 2024 According to a SpyGlass Pharma media release, company prepares for End of Phase II meeting with the FDA to advance its Drug Delivery Platform into Phase III pivotal studies.